ArticleHIV medicine2026
Monitoring the HIV response for trans people in Europe and Central Asia.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThis paper aims to present available data on national responses to HIV for trans populations related to national policies, legal environments and prevention programmes, as reported by European and Central Asian countries.
methodsBetween February and April 2024, the European Centre for Disease Prevention and Control disseminated an online questionnaire to nominated National HIV Focal Points in Europe and Central Asia to monitor implementation of the Dublin Declaration on partnership to fight HIV/AIDS. This included questions on national HIV policies, legal environments, prevention programmes, the continuum of HIV care and avoidance of healthcare.
resultsTwenty-three of 50 countries involve trans people in the content and development of national HIV strategies and policies related to their health. Two of 47 countries enact punitive legislation against trans people, and there is some evidence of healthcare seeking avoidance among trans people due to stigma in healthcare settings. In half of reporting countries (23/46), trans people have free (no cost) access to sexually transmitted infection testing and treatment. Limited availability and quality of national HIV data on the number of trans people diagnosed, treated and virally suppressed prevent the accurate measurement of progress towards global HIV targets for this key population.
conclusionsTrans people are to a lesser extent than other key populations addressed in national HIV policies and strategies, and the data available from countries suggest lower levels of access to services because of costs, unsupportive legal environments and avoidance of seeking healthcare services. Without comprehensive and trans-inclusive data collection, national and regional HIV responses may risk neglecting the specific needs of trans people in HIV prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.